Menu
Recruiting NCT05922540

a Cohort Study of Ischemic Cerebrovascular Disease

Observational Ischaemic Stroke

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Intravenous thrombolysis.
Who it may be relevant to
Registry conditions: Ischaemic Stroke. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

a Prospective, Multicenter Cohort Study of Ischemic Cerebrovascular Disease

Overview

This study aims to establish a multicenter, large-scale, prospective cohort of patients with ischemic stroke. Various biological samples such as blood, feces, and urine are collected to identify biomarkers associated with ischemic stroke. By integrating demographic information, clinical indicators, imaging parameters, and biomarker parameters, the study aims to develop risk assessment, early warning, and prognosis prediction models. Additionally, the study aims to identify key genes and explore relevant signaling pathways related to ischemic stroke.

Interventions

  • Other Intravenous thrombolysis
    Intravenous thrombolysis with alteplase within the time window of stroke onset in stroke patients

Primary outcome measures

  • Cerebrovascular events [Time frame: 3 months of onset in patients]
  • mRS scores [Time frame: 3 months of onset in patients]

Eligibility criteria

Inclusion criteria

  • Clinical diagnosis of ischemic stroke.
  • Age ≥ 18 years.
  • Signed informed consent form.

Exclusion criteria

  • Patients with moderate to severe mental disorders or dementia who cannot cooperate to complete the informed consent and follow-up procedures.
  • Patients with neurological functional impairment caused by conditions such as migraine aura, epilepsy, or other non-ischemic strokes.
  • Agitated patients who cannot cooperate with imaging examinations.
  • Pregnant or lactating patients, as well as those planning to become pregnant within 90 days.
  • Patients with concurrent malignant tumors or severe systemic diseases with an expected survival period of less than 90 days.
  • Patients who have participated in other clinical studies within 30 days prior to enrollment or are currently participating in other interventional clinical studies.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Cohort

Study locations

China · 1 center
  • Xiangya Hospital, Central South University — Hunan

Identifiers

NCT: NCT05922540 · 202304068

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗